Key Points Wall Street analysts have raised price targets on Abbott, citing accelerating growth in its Medical Devices segment. Abbott's diabetes, electrophysiology, and new Exact Sciences cancer-screening businesses are driving stronger sales and earnings. Abbott's future dividend increases depend on turning growth investments into stronger cash flow. 10 stocks we like better than Abbott Laboratories › A Dividend King is a company that's raised its dividend for at least 50 years consecutively. Abbott Laboratories (NYSE: ABT) , for example, is one such company, having raised its dividend for 54 straight years. But that's not really why Wall Street is bullish on the stock.
Publicznie pokazujemy glowna mysl. Utworz darmowe konto, aby czytac caly artykul, zapisac go, omowic i polaczyc z kontekstem rynkowym oraz OSINT.